orantinib has been researched along with Sensitivity and Specificity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, M; Hiramatsu, Y; Kamiya, K; Kawabata, T; Kikuchi, H; Konno, H; Ohta, M; Tanaka, T; Yamamoto, M | 1 |
| Adams, A; Asad, Y; Cropp, G; Judson, I; O'Donnell, A; Raynaud, F; Workman, P | 1 |
1 trial(s) available for orantinib and Sensitivity and Specificity
| Article | Year |
|---|---|
Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Indoles; Oxindoles; Propionates; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2003 |
1 other study(ies) available for orantinib and Sensitivity and Specificity
| Article | Year |
|---|---|
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
Topics: Angiogenesis Inhibitors; Animals; Colon; Colonic Neoplasms; Disease Models, Animal; Drug Delivery Systems; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Propionates; Pyrroles; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Sensitivity and Specificity; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |